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Genetic variation is associated with differences in the function of the brain as well as its susceptibility to
disease. The common H1 haplotypic variant of the microtubule-associated protein tau gene (MAPT) has
been related to an increased risk for Parkinson’s disease (PD). Furthermore, among PD patients, H1
homozygotes have an accelerated progression to dementia. We investigated the neurocognitive corre-
lates of MAPT haplotypes using functional magnetic resonance imaging. Thirty-seven nondemented
patients with PD (19 H1/H1, 18 H2 carriers) and 40 age-matched controls (21 H1/H1, 19 H2 carriers) were
scanned during performance of a picture memory encoding task. Behaviorally, H1 homozygosity was
associated with impaired picture recognition memory in PD patients and control subjects. These im-
pairments in the H1 homozygotes were accompanied by an altered blood-oxygen level-dependent
response in the medial temporal lobe during successful memory encoding. Additional age-related dif-
ferences in blood-oxygen level-dependent response were observed in the medial temporal lobes of H1
homozygotes with PD. These results suggest that common variation in MAPT is not only associated with
the dementia of PD but also differences in the neural circuitry underlying aspects of cognition in normal
aging.
 2015 Elsevier Inc. All rights reserved.1. Introduction
Neurodegenerative diseases of the central nervous system
represent a formidable challenge in our aging society. Parkinson’s
disease (PD) affects 1%e2% of the population over the age of 65 years,
and although it is classically regarded as a movement disorder,
associated cognitive impairment is a key determinant of quality of
life and care requirements. Heterogenous mild cognitive deﬁcits are
present even at the time of diagnosis (Foltynie et al., 2004; Yarnall
et al., 2014) and dementia affects 50%e80% of patients in the laterNeurosciences, University of
t of Clinical Neurosciences,
.: þ44 1223 331160; fax: þ44
rg.uk (S.E. Winder-Rhodes),
ll rights reserved.disease stages (Aarsland et al., 2003; Williams-Gray et al., 2013). The
executive cognitive deﬁcits in PD are thought to be related to dis-
turbances in frontostriatal dopaminergic systems (Williams-Gray
et al., 2007), but there is also substantial evidence linking aspects
of PD dementia to the progression of a “posterior cortical” syndrome
of cognitive impairment (Williams-Gray et al., 2009) and the spread
of Lewy body-type pathology into cortical and limbic structures
(Aarsland et al., 2005).
Genetic association studies have identiﬁed the gene encoding
themicrotubule-associated protein tau,MAPT, as a key risk locus for
several neurodegenerative disorders including PD (Caffrey and
Wade-Martins, 2007). Tau is involved in the assembly and stabili-
zation of microtubules but forms characteristic aggregates in
several neurodegenerative diseases collectively known as the
tauopathies. Although PD is not typically regarded as a tauopathy
and is instead characterized by alpha-synuclein pathology, a link
between MAPT and PD is now well established. Of the 2 common
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overwhelming evidence that H1 is signiﬁcantly overrepresented in
PD patients relative to control subjects (Goris et al., 2007; Simón-
Sánchez et al., 2009). In addition, it has emerged that these MAPT
haplotypes are associated with the cognitive heterogeneity of PD.
For example, our prospective study of a community-based PD
cohort followed from diagnosis revealed that patients who are H1
homozygotes (H1/H1) had an accelerated rate of cognitive decline
relative to H2 carriers (H1/H2, H2/H2) (Goris et al., 2007). These
effects of MAPT interacted with age, such that the rate of cognitive
decline was dependant on age in H1 homozygotes but not in H2
carriers (Goris et al., 2007). Over a 10 year follow-up period, MAPT
H1 homozygosity continued to be one of the key predictors of de-
mentia after adjustment for age (Evans et al., 2011; Williams-Gray
et al., 2013). The same association has been reported in an inde-
pendent cross-sectional study of 202 patients, in which there was a
greater overrepresentation of the H1 haplotype among PD patients
with dementia than those without (Setó-Salvia et al., 2011).
Despite compelling evidence that the common H1 versus H2
MAPT haplotypes are associated with differences in the presenta-
tion of PD, the relationship between haplotypic variation in MAPT,
cognition, and underlying brain function remains relatively unex-
plored. To investigate the basis of the genotype-phenotype corre-
lations, we used functional magnetic resonance imaging (fMRI) in a
group of genotyped patients with PD and age-matched controls.
Functional MRI has proven to be a sensitive indicator of presymp-
tomatic dementia processes and has revealed altered patterns of
brain function associated with genetic risk for Alzheimer’s disease
(AD) even in the absence of differences in cognitive function (Bondi
et al., 2005; Bookheimer et al., 2000).
The cognitive task chosen for this study was a previously vali-
dated memory test involving picture encoding (Dove et al., 2006).
We selected this task on the basis that (1) memory has been
identiﬁed as one of the most commonly affected cognitive domains
in PD (Aarsland et al., 2010; Yarnall et al., 2014); and (2) PD de-
mentia has been hypothesized to develop at least in part from a
syndrome of cognitive impairment characterized by deﬁcits in
posterior cortical function (Williams-Gray et al., 2009). We used
event related fMRI to measure brain activation during different
subcomponents of memory encoding, focusing our analysis on
medial temporal lobe regions, particularly the hippocampus, which
are known to be crucial for the registration of new information
(Fernández et al., 1998; Milner et al., 1998). Our aims were toTable 1
Clinical and demographic characteristics of the participants
Variable Controls PD patients
H1/H1 H2 carriers H1/H1
N 21 19 19
Sex (male: female) 13:8 11:8 11:8
Age (y) 62.6  5.6 65.7  4.8 64.0  7.2
ACE-R (%) 92.6  2.4 95.8  3.0 95.4  3.8
ACE-R memory (/26) 24.5  1.9 24.0  2.4 24.2  1.9
BDI 4.2  4.3 5.5  5.0 6.2  3.0
NART 122.4  4.7 121.9  6.4 117.9  8.0
Years of education 15.3  3.5 15.1  3.0 13.7  2.9
H&Y NA NA 1.8  0.4
MDS-UPDRS 3 NA NA 28.2  11.0
Years since diagnosis NA NA 6.7  2.4
Actual L-dopa (mg) NA NA 329.0  231.
Equivalent L-dopa (mg) NA NA 1202.6  685
Values are expressed as group means  standard deviations for continuous variables. p
carriers, control H1/H1, control H2 carriers); 2-tailed t tests comparing groups by MAPT
presented without correction for multiple comparisons.
Key: ACE-R, Addenbrooke’s Cognitive Examination (revised version); ANOVA, analysis o
Movement Disorders Society Uniﬁed Parkinson’s Disease Rating Scale Section 3 (moto
Parkinson’s disease.explore the relationship between the common MAPT haplotypes
and memory function and to determine whether this relationship
varied with the presence of PD and increasing age.
2. Methods
2.1. Participants
Data are presented from 77 right-handed participants who un-
derwent MRI scanning at the Medical Research Council (MRC)
Cognition and Brain Sciences Unit, Cambridge (Table 1). All partic-
ipants were asked to abstain from caffeine for at least 3 hours and
alcohol for 12 hours before the scan. They were offered a monetary
reimbursement for their time at standard local MRC rates (£10/h)
with a contribution toward travel costs. On the day of scanning, all
participants completed the Addenbrooke’s Cognitive Assessment
Revised Version (ACE-R; Mioshi et al., 2006) incorporating the
Mini-mental State Examination (Folstein et al., 1975); National
Adult Reading Test (NART; Nelson, 1982) as an estimate of pre-
morbid IQ; and the revised Beck Depression Inventory (BDI; Beck
et al., 1961). Participants were required to have no signiﬁcant sub-
jective or objective cognitive deﬁcit (Mini-mental State Examina-
tion score26), no history of head trauma, and nomajor depression
(BDI 18). The study was approved by the Cambridgeshire 2
Research Ethics Committee, UK (LREC number: 08/H0308/355) and
the Addenbrooke’s Research and Development Department. Writ-
ten informed consent was obtained from all volunteers.
Patients were recruited via the PD research clinic at the John van
Geest Centre for Brain Repair (BRC). All fulﬁlled the PD Society Brain
Bank Criteria for idiopathic PD (Gibb and Lees, 1988) with mild-
moderate disease (HYS 3) (Hoehn and Yahr, 1967) and remained
on their usual medications during testing. Each patient’s dopami-
nergic drug regime was converted to an equivalent L-dopa dose
(Williams-Gray et al., 2007): Equivalent L-dopa dose ¼ (L-dopa
[ 1.2 if 10 mg selegiline OR  1.1 if 5 mg selegiline]) þ
(pramipexole  400) þ (ropinirole  40) þ (cabergoline 160) þ
(pergolide  200) þ (bromocriptine  10) þ (lisuride  160) þ
(rasagiline  100), all doses in mg. Patients’ motor features were
assessed on the day of scanning by a single assessor using Section 3
of the MDS-UPDRS (Goetz et al., 2008).
Control subjects were recruited from the volunteer panel at the
MRC-CBU and via local advertisement andwere screened for past or
current neurologic problems.p-value of group differences
H2 carriers All groups MAPT PD vs. control
18 d d d
12:6 0.94 0.85 0.85
63.6  7.0 0.45 0.31 0.81
94.9  3.5 0.14 0.98 0.07
23.7  2.9 0.76 0.37 0.55
8.7  5.3 0.03 0.09 0.02
117.2  8.3 0.05 0.69 0.01
13.9  3.4 0.38 0.96 0.08
1.7  0.5 0.65 0.65 NA
28.0  12.4 0.97 0.97 NA
6.8  4.0 0.98 0.98 NA
7 361.9  208.2 0.65 0.65 NA
.2 939.7  526.4 0.20 0.20 NA
values are derived from 1-way ANOVAs comparing all 4 groups (PD H1/H1, PD H2
haplotype and disease presence; and c2 tests for categorical variables. Results are
f variance; BDI, Beck Depression Inventory; H&Y, Hoehn and Yahr; MDS-UPDRS 3,
r features); NA, measure not applicable; NART, National Adult Reading Test; PD,
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Potential participants provided either a saliva sample via a
postal Oragene kit (DNA Genotek Inc, Ontario) or a venous blood
sample for genetic analysis before invitation for the scanning phase
of the study and were selected on the basis of genotype. DNA was
extracted from venous blood samples using standard salting out
methods or from saliva samples according to the manufacturer’s
instructions. Genotyping for rs9468 (tagging MAPT H1 vs. H2
haplotype) was performed using a Taqman allelic discrimination
assay and run on an HT7900 detection system (Applied Biosystems)
(Goris et al., 2007).2.3. Experimental paradigm
Participants viewed a series of abstract pictures in the scanner
(Fig. 1A) and were asked to commit them to memory. Pictures were
presented for 4 seconds in blocks of 6, with a ﬁxation shown for
1 second betweenpictures and 20 seconds between blocks. Participants
viewed a total of 36 different pictures in the scanner, 18 of which were
then presented twice. Participants were not required to make any re-
sponses during the scan. Memory for the pictures was tested approxi-
mately 20 minutes after the presentation of the pictures in the scanner
(Fig. 1B). During the memory test, a series of 72 pictures were shown,
half of which had been displayed at least once in the scanner and the
remainder of which were novel distractor pictures. Participants were
asked to indicate whether they had seen each picture before.Fig. 1. The abstract pictures memory encoding task. (A) A typical series of stimuli. (B) A
typical presentation in the post-scanner test of recognition. Participants responded
using the arrow keys on the keyboard. (C) Performance on the post-scanner test of
recognition. d’ scores are shown (higher score represents greater discrimination during
recognition memory). Group means are plotted. Error bars indicate  1 SEM. Asterisk
denotes p < 0.05 based on main effects of repeated measures ANOVAs. There were
additional signiﬁcant effects of the number of presentations and disease status (PD
patients vs. control subjects). Abbreviations: ANOVA, analysis of variance; PD, Parkin-
son’s disease; SEM, standard error of the mean.2.4. Behavioral data analysis
For demographic and clinical characteristics, 1-way analyses of
variance (ANOVAs) and c2 tests were used to assess between-group
differences in quantitative and categorical variables, respectively.
Student t tests (2 tailed) were then used to compare the groups (PD
vs. controls; H1 homozygotes vs. H2 carriers).
The behavioral outcome measure for the study was the number
of pictures correctly classiﬁed as having been previously seen. As
this task required participants to select one of 2 responses for each
image, d’ values were calculated for each individual to take into
account the relative proportions of true and false hits, therefore
giving a measure of performance independent of response bias
(Dove et al., 2006). Outliers (n¼ 2) were identiﬁed based on Tukey’s
Hinges percentile data and transformed using winsorization.
Shapiro-Wilks tests conﬁrmed that the scores within each group
were normally distributed. The d’ values were entered into a
repeated measures ANOVA with the number of previous pre-
sentations (1 vs. 2) as awithin-subjects factor, and disease (patients
vs. controls) and genetic group (H1 homozygotes vs. H2 carriers) as
between-subject factors. Signiﬁcant main effects and interactions
were explored using least signiﬁcant difference tests and Student t
tests.
Data analyses were performed using the Statistical Package for
Social Sciences (version 21.0: SPSS, Chicago IL), and the threshold
for statistical signiﬁcance was considered to be p  0.05. Where
Mauchly test indicated that the assumptions of sphericity had been
violated, Greenhouse-Geisser estimates were used.
2.5. Imaging acquisition
All pictures were acquired on a Siemens 3T Tim Trio Scanner
(Siemens Medical Systems, Erlangen, Germany) with a 12-channel
head coil. A T1-weighted structural image was acquired for each
participant using a high resolution MPRAGE sequence (Repetition
time¼ 2250ms, Echo time¼ 2.99ms, ﬂip angle¼ 9, ﬁeld of view¼
256 mm  240 mm  192 mm, voxel size ¼ 1 mm isotropic).
Structural scans of all participants were screened for gross abnor-
malities by a radiologist.
T2-weighted echo-planar pictures depicting blood-oxygen
level-dependent (BOLD) signals were acquired using a standard
Siemens EPI sequence for fMRI. The ﬁrst 10 pictures (20 seconds)
were discarded to avoid T1-equilibrium effects. Each image con-
sisted of 32 slices of 3 mm thickness with a 25% interslice gap, with
an in-plane resolution of 3  3 mm. The repetition time was 2
seconds. Slices were angled away from the orbits to avoid signal
dropout because of magnetic susceptibility inhomogeneity. Stimuli
were presented on a computer screen with a resolution of 1024
pixels which was visualized using a mirror positioned within the
scanner at a viewing distance of 90 mm, such that 37 pixels sub-
tended a visual angle of 1.
2.6. MRI preprocessing
Imaging data were preprocessed using Statistical Parametric
Mapping software (SPM8; Wellcome Department of Imaging
Neuroscience, UCL, UK) implemented in MATLAB (MathWorks).
SPM8processingwas implemented by the “aa”batch system (http://
imaging.mrc-cbu.cam.ac.uk/imaging/AutomaticAnalysis). Struc-
tural MRI data were used for spatial normalization of the fMRI data
andalso for voxel-basedmorphometric analysis of brain structure. In
the voxel-based morphometric analysis, gray matter volume was
extracted for each participant from hippocampal, fusiform, and
parahippocampal gyri regions of interest deﬁned using the Auto-
matic Anatomical Labeling atlas (AAL; Tzourio-Mazoyer et al., 2002),
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models (see Supplementary Materials).
For each participant, fMRI volumes were motion corrected, slice
time acquisition corrected, co-registered to the structural MPRAGE,
segmented and normalized to the standard Montreal Neurological
Institute echo-planar imaging template using the SPM8 uniﬁed
segmentation, and smoothed with an 8 mm full width at half
maximum Gaussian kernel. Six subject-speciﬁc movement predic-
tor functions consisting of rotations and translations in the X, Y, and
Z planes were extracted from this process, and the root mean
squared of the “scan to scan” differences were calculated for each
participant, representing the average displacement in space. Com-
parison of these values using repeated measures ANOVA with a
within-subjects factor (parameter) and 2 between-subjects factors
(PD patients vs. controls andMAPT H1 homozygotes vs. H2 carriers)
conﬁrmed no differences in motion associated with PD or MAPT
haplotype.
2.7. Single-subject level fMRI analysis
Events during scanning were categorized into 3 types, namely:
(1) presentation of pictures that were shown only once; (2) ﬁrst
presentation of pictures that were shown twice; and (3) second
presentation of pictures that was shown twice. For each individual,
every image was further categorized according to whether it was
subsequently recognized in the post-scanner test (“remembered”)
or not (“non-remembered”). The factorial design of event type (3)
and subsequent memory (2) resulted in 6 conditions.
Fixed effects analyseswere carried out at the single subject level.
Whole brain activation maps were generated for each participant
for the 6 conditions. Event onsets related to the time at which the
stimulus appeared on the screen and durations related to the length
of time for which the stimulus was shown. These onset and dura-
tion timings were convolved with a canonical haemodynamic
response function to account for the lag between neural activity
and the BOLD signal. Individual participant models included the 6
subject-speciﬁc movement predictor functions (see previously
mentioned data). For each individual, 2 contrasts were made. The
ﬁrst contrast consisted of “remembered”minus “non-remembered”
pictures and included only pictures that were shown once in the
scanner to achieve one-to-one mapping between viewing the pic-
ture and subsequent recognition. The aim of this contrast was to
identify regions that were speciﬁcally involved in successful
memory encoding (Kim, 2011). The second contrast consisted of all
events minus baseline and allowed us to look at more general dif-
ferences associated with engagement in the task that would occur
across both successful and unsuccessful trials.
2.8. Group level fMRI analysis
We performed a hierarchical series of analyses of the fMRI data
based on our anatomically constrained hypotheses and the antici-
pated modest effect size of a single genetic variant on activation.
First, we tested the hypothesis that differences associated with
memory functionwould be seen in the hippocampus by means of a
region of interest (ROI) analysis. Second, we performed a whole-
brain voxel wise analysis with correction applied, to identify clus-
ters of activation differences within the temporal lobes. Finally, we
performed an exploratory whole-brain analysis to facilitate meta-
analysis.
2.8.1. Hippocampal ROI analysis
Mean activation data from hippocampal ROIs, deﬁned using the
AAL atlas, were extracted from each participant using the MarsBaR
toolbox for each of the 2 contrasts (Brett et al., 2002). Data werethen winsorised at 2.5 SDs and then subjected to a 2  2  2
ANOVA in which the between-subject factors were MAPT haplo-
type (H1 homozygotes vs. H2 carriers) and PD (patients vs. control
subjects) and the within-subject factor was hemisphere (left vs.
right).
2.8.2. Temporal lobe clusters of activation and whole brain analyses
We then performed additional voxel-wise analyses, to detect
activation differences outside the hippocampus as well as regional
differenceswithin the hippocampus thatmay have been obscured by
averaging across the whole ROI. We used robust nonparametric
cluster-based permutation analysis as implemented in the Cam-
bridge Brain Activation software (CamBA v2.0.0; www-bmu.
psychiatry.cam.ac.uk/software/; Bullmore et al., 1999; Suckling and
Bullmore, 2004). Speciﬁcally, individual subjects’ activation maps
for each of the 2 contrasts were entered into voxel-wise ANOVAs. The
ﬁrst model included only PD patients with MAPT haplotype (H1
homozygotes vs. H2 carriers) as a between subjects factor. Age, sex,
equivalent L-dopa, MDS-UPDRS motor score, and laterality of motor
features (left vs. right) were then added as covariates. The second
model included only controls, with MAPT haplotype (H1 homozy-
gotes vs. H2 carriers) as a between subjects factor, and the third
included PD patients and control subjects, with PD (patients vs.
control subjects) and MAPT haplotype (H1 homozygotes vs. H2 car-
riers) as between subject factors. Regions activated during each of
the 2 contrasts of interest were ﬁrst identiﬁed by conducting a
second-level group analysis across all 77 subjects. Linear contrasts
were then deﬁned to compare activation between groups.
We constructed an inclusive mask from all the temporal lobe
anatomic regions deﬁned in the AAL templates, to target our
analysis on regions pertinent to memory. To stringently control for
multiple comparisons, a cluster-based family wise error correction
was applied in CamBA, such that the probability of one or more
false positive clusters within the entire temporal lobe mask was p<
0.05 (for detailed description see Bullmore et al., 1999; Suckling and
Bullmore, 2004). This cluster-based correction was applied to vox-
els that exceeded an uncorrected threshold of p < 0.05 in a whole-
brain voxel wise analysis. The resultant statistical maps showing
clusters that survived cluster correction (p < 0.05 FWE corrected)
were rendered onto an MNI-space template.
Finally, in recognition of the potential contributions from regions
outside of the temporal lobes, and with an aim to support future
meta-analyses, we conducted an additional exploratory whole-brain
analysis using an uncorrected voxel-wise threshold of p < 0.01. Full-
factorial models were constructed as described previously, and the
peak coordinates of activation differences associated with MAPT
haplotype are reported in the Supplementary Materials. We note
that our main inferences do not rely on these exploratory tests.
2.8.3. Correlations with age
Correlations between age and activation were explored by
extracting mean activation data from spherical ROIs with a 5 mm
radius placed at the peak activation coordinates (left and right
hippocampus) from our cluster-based analysis of contrast 1
(remembered minus non-remembered items). These ROIs were
selected as, by the nature of the contrast, they are likely to represent
key regions associated with successful task performance. Activation
data were averaged across all voxels within the ROIs and Pearson
correlations between activation and age performed in SPSS. To test
for differences between the correlations in the groups, each cor-
relation coefﬁcient was converted into a z-score using Fisher r-to-z
transformation. Then, making use of the sample size used to obtain
each coefﬁcient, these z-scores were compared using formula 2.8.5
from Cohen and Cohen (1983) via the online application available at
http://quantpsy.org (Preacher, 2002).
Fig. 2. Activation in the hippocampal regions of interest (ROI) during successful encoding
(contrast 1: successful minus unsuccessful encoding) in all participants stratiﬁed by MAPT
haplotype. ROIs were deﬁned anatomically using AAL templates, and activation is
expressed in arbitrary units using the mean parameter estimates from the ROI. *p < 0.05
(2-tailed t tests). Error bars indicate 1 SEM. Abbreviations: AAL, anatomical labeling atlas;
PD, Parkinson’s disease; SEM, standard error of the mean.
Fig. 3. BOLD activations associated with performance of the memory encoding task.
(A) Contrast 1: Activation during successful encoding (i.e. remembered minus non-
remembered pictures) across all participants. (B) Effect of MAPT haplotype on Contrast
1 activation in patients with PD. (C) Effect of MAPT haplotype on Contrast 1 activation
in control subjects. (D) Interaction between MAPT haplotype and PD (PD patients vs.
control subjects) on Contrast 1 activation. (E) Contrast 2: Activation during overall task
performance minus rest across all participants. (F) Effect of MAPT haplotype on
S.E. Winder-Rhodes et al. / Neurobiology of Aging xxx (2015) 1e10 53. Results
3.1. Association between MAPT haplotype and behavioral
performance
Participants in all 4 groups (PDMAPT haplotype) were matched
in terms of overall cognitive performance on the ACE-R (Table 1);
speciﬁcally, there were no between-group differences on the mem-
ory subsection of this assessment (F¼ 0.39, p¼ 0.760). NARTand BDI
scores differed between patients and control subjects, and these
scores were therefore added as covariates in behavioral analyses.
There were, however, no signiﬁcant differences between H1 homo-
zygotes and H2 carriers regardless of disease status.
Across all participants, pictures were categorized as previously
seen or unseen more accurately thanwould be predicted by chance
(1 sample t test: d’ scores vs. “0,” p < 0.001) (Fig. 1C). As expected,
there was a signiﬁcant effect of the number of presentations
(F[1,73] ¼ 106.65, p < 0.001), with enhanced memory for pictures
shown twice. Critically, there was a signiﬁcant main effect of MAPT
haplotype (F[1,73] ¼ 4.95, p ¼ 0.029) with H2 carriers out-
performing H1 homozygotes. Overall, controls made more correct
responses than PD patients (F[1,73] ¼ 9.23, p ¼ 0.003); however,
there was no interaction between PD and MAPT haplotype on per-
formance (F[1,73] ¼ 0.66, p ¼ 0.798). Inclusion of sex and age as
covariates revealed an additional effect of sex (F[1,71] ¼ 5.38, p ¼
0.023) which corresponded to better performance in females than
males, but no main effect of age (F[1,71] ¼ 0.17, p ¼ 0.684). The
signiﬁcant effects of MAPT haplotype and PD remained after addi-
tion of NART and BDI (adjusted to group means) as covariates.
Separate ANOVAs in the patients and control subjects showed that
the effects of MAPT haplotype were below the threshold for sig-
niﬁcance in the 2 groups (controls F[1,38] ¼ 3.23, p ¼ 0.080; PD
patients F[1,35] ¼ 1.85, p ¼ 0.183).Contrast 2 activation in patients with PD. (G) Effect of MAPT haplotype on Contrast 2
activation in control subjects. (H) Interaction between MAPT haplotype and PD (PD
patients vs. control subjects) on Contrast 2 activation. All effects of MAPT correspond
with increased activation in H2 carriers compared with H1 homozygotes (H1/H1).
Activation that survived permutation-based cluster correction (p < 0.05 FWE cor-
rected) within a predeﬁned inclusive mask of the temporal lobe region of interest
(green) is displayed. Abbreviations: BOLD, blood-oxygen level-dependent; PD, Par-
kinson’s disease.3.2. Association between MAPT haplotype and BOLD response
during successful encoding
In our ﬁrst contrast, we looked at activation during non-
remembered events subtracted from remembered events toestablish activation patterns associated with successful encoding.
Mean activation data were ﬁrst extracted from the bilateral
anatomically predeﬁned hippocampal ROIs. An averaged t contrast
suggested an overall involvement of this region in successful
encoding; however, this did not reach signiﬁcance (left hippo-
campus: t ¼ 1.39, p ¼ 0.084; right hippocampus: t ¼ 1.30, p ¼
0.099). A 2 2 2 ANOVA (PDMAPT hemisphere) did however
reveal a signiﬁcant main effect of MAPT haplotype on activation in
the hippocampus bilaterally in both patients and controls (F¼ 4.00,
p < 0.05). Two-tailed Student t tests conﬁrmed that this corre-
sponded to signiﬁcantly lower activation in H1 homozygotes than
in H2 carriers in the right (t ¼ 1.84, p ¼ 0.035) and left (t ¼ 2.22, p¼
0.015) hippocampal ROIs (Fig. 2). There was no main effect of PD no
signiﬁcant additive effects of PD and MAPT haplotype nor any in-
teractions (all p > 0.4).
Table 2
Activation differences associated with MAPT haplotype during memory task performance
Contrast Contrast activation areas Cluster size
(voxels)
Peak value coordinates
x y z
Contrast 1: successful encoding (remembered minus non-remembered)
All participants; H2 carriers > H1/H1
Cluster 1 L hippocampus, L parahippocampal gyrus, L amygdala, L fusiform gyrus,
L inferior temporal gyrus
927 36 34 8
Cluster 2 L Heschl’s gyrus, L superior temporal gyrus, L middle temporal gyrus, L
inferior temporal gyrus
1687 48 48 4
Cluster 3 R hippocampus, R parahippocampal gyrus, R fusiform, R Heschl’s gyrus,
R superior temporal gyrus, R superior temporal pole, R middle temporal
gyrus, R middle temporal pole, R inferior temporal gyrus
2831 42 18 0
Patients with PD; H2 carriers > H1/H1
Cluster 1 L hippocampus, L parahippocampal gyrus, L amygdala, L fusiform gyrus,
L inferior temporal gyrus
619 36 32 10
Cluster 2 R hippocampus, R parahippocampal gyrus, R amygdala, R fusiform
gyrus, R inferior temporal gyrus
484 44 16 24
Controls; H2 carriers > H1/H1
Cluster 1 L hippocampus, L parahippocampal gyrus, L fusiform gyrus 230 30 34 26
Contrast 2: overall task performance (all events minus baseline)
PD  MAPT interaction
Cluster 1 L hippocampus, L parahippocampal gyrus, L amygdala, L fusiform gyrus,
L inferior temporal gyrus
811 20 24 20
Cluster 2 R hippocampus, R parahippocampal gyrus, R amygdala, R fusiform
gyrus, R inferior temporal gyrus
259 58 26 16
Patients with PD; H2 carriers > H1/H1
Cluster 1 L hippocampus, L parahippocampal gyrus, L fusiform gyrus, L superior
temporal gyrus, L middle temporal gyrus, L inferior temporal gyrus
2102 24 20 22
Cluster 2 R hippocampus, R parahippocampal gyrus, R fusiform gyrus, R superior
temporal gyrus, R superior temporal pole, R middle temporal gyrus, R
inferior temporal gyrus
2316 50 38 20
Controls; H2 carriers > H1/H1
Cluster 1 R superior temporal gyrus, R middle temporal gyrus 582 40 54 10
Details are provided for clusters of activation surviving cluster-based correction for multiple comparisons within an inclusive mask of the temporal lobes (p < 0.05 FWE
corrected). There were no signiﬁcant interactive effects of MAPT haplotype (H1 homozygotes vs. H2 carriers) and PD (patients vs. controls) for contrast 1 and no signiﬁcant
effect ofMAPT haplotype (H2 carriers > H1/H1) across all participants for contrast 2. Coordinates listed are in Montreal Neurological Institute (MNI) standard space. Anatomic
labels are derived from the AAL atlas.
Key: FWE, Family-wise error; L, left; PD, Parkinson’s disease; R, right.
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memory encoding was associated with extensive activation in the
medial temporal lobes bilaterally (Fig. 3A). Among the PDpatients,H1
homozygotes had less activation than H2 carriers across
the hippocampus, inferior temporal lobes, fusiform, and para-
hippocampal gyri bilaterally at the cluster-corrected threshold (p <
0.05 FWE corrected; Fig. 3B; Table 2). These effects remained, and no
other signiﬁcant effects or interactionswere found, after the addition
of covariates. Analyzing control data revealed similar differences
associated with MAPT haplotype with H1 homozygotes having less
activation than H2 carriers especially within a left temporal lobe
cluster incorporating the hippocampus (Fig. 3C; Table 2). Including
patients and control subjects in a 2  2 full factorial design (PD 
MAPT) showednomain effect of PDnor anyother signiﬁcanteffects or
interactions (Fig. 3D). Examination of data extracted from peak acti-
vation clusters revealednocorrelationsbetweenactivation and age in
any of the patient or controlMAPT haplotype subgroups.
3.3. Association between MAPT haplotype and BOLD response
during overall performance
In our second contrast, all events were averaged to establish
activation patterns associated with overall task performance rela-
tive to rest. Mean activation data were ﬁrst extracted from the
bilateral anatomically deﬁned hippocampal ROIs. An averaged
t contrast showed that therewas a strong hippocampal activation in
this task (left hippocampus: t¼ 3.99, p< 0.001; right hippocampus:
t ¼ 4.12, p < 0.001). A 2  2  2 ANOVA (PD MAPT  hemisphere)
did not reveal any signiﬁcant effects of MAPT haplotype or PD, nor
any interactions.Voxel-wise analysis of this contrast revealed that general
engagement in the task was associated with signiﬁcant activation
across a network of regions including the visual processing areas,
frontoparietal cortices, and the medial temporal lobes (Fig. 3E). In
patients with PD, there was a signiﬁcant effect of MAPT haplotype
with less activation in H1 homozygotes than H2 carriers bilaterally
in the hippocampus, inferior temporal lobe, fusiform, and para-
hippocampal gyri at the cluster-corrected threshold (p < 0.05 FWE
corrected; Fig. 3F; Table 2). Addition of covariates revealed no other
signiﬁcant effects of L-dopa, motor scores, or disease lateralization.
In contrast, the control subjects did not exhibit a signiﬁcant effect of
MAPT haplotype within the medial temporal lobes (Fig. 3G).
Including patients and control subjects in a 2  2 full factorial
model revealed no main effect of PD or MAPT haplotype; however,
there was a signiﬁcant interaction between MAPT haplotype and
PD, supporting the view that there were differential effects ofMAPT
haplotype in PD patients and control subjects (Fig. 3H; Table 2).
To explore the effects of age on overall task-related activity, data
from the peak activation clusters in the hippocampus (deﬁned in
contrast 1) were extracted. Only within the group of PD H1 ho-
mozygotes was there a signiﬁcant negative correlation between
activation and age (r[17]¼0.61, p< 0.01), with the correlations in
the other 3 groups being close to zero (all jrj  0.1; Fig. 4). One H1
homozygotewith PD had a valuewhichwasmore than 2.5 SDs from
the mean; however, the correlation between age and activation
remained signiﬁcant in this group after replacing this outlier with
the nearest value in the data set (r[17] ¼ 0.52, p < 0.01). Fisher
tests showed that the negative correlation in the PD H1 homozy-
gotes differed signiﬁcantly from the correlation collapsed across all
other groups (z ¼ 2.25, p ¼ 0.024 two tailed). Comparing the
Fig. 4. Correlations between age and hippocampal activation during overall task performance. Mean activation data for contrast 2 (“all events minus baseline”) was extracted
from peak activation coordinates deﬁned in contrast 1 (“successful encoding”). Values are plotted after winsorizing one outlier (>2.5 SD from mean) in the group of H1 ho-
mozygotes (H1/H1) with Parkinson’s disease (PD). A signiﬁcant negative correlation (p < 0.05) between age and activation is seen in H1 homozygotes with PD. Abbreviation: SD,
standard deviation.
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differed signiﬁcantly from the correlations in the control groups
(control H1/H1: z ¼ 2.36, p ¼ 0.018; control H2 carriers:
z ¼ 0.198, p ¼ 0.048) and with a trend difference from the cor-
relation in the PD H2 carriers (z ¼ 1.72, p ¼ 0.085).
4. Discussion
The aim of this study was to deﬁne differences associated with
common haplotypic variation inMAPT duringmemory formation in
patients with PD and healthy age-matched control subjects. Brain
activation was measured using fMRI as participants intentionally
memorized abstract pictures and their ability to remember these
pictures was subsequently assessed in a test of recognition. To our
knowledge, this is the ﬁrst study to investigate the neurocognitive
correlates of haplotypic variation in MAPT in patients with PD and
control subjects using fMRI, and we anticipate that our ﬁndings will
contribute to our understanding of the relationship between this
common genetic variant, cognitive dysfunction, and dementia in PD.
Behaviorally, we found that across a group of 77 nondemented
patients with PD and age-matched controls, MAPT H1 homozygotes
had a poorer ability to recognize pictures seen in the scanner than
their H2 carrier counterparts. The effects ofMAPT haplotype did not
reach signiﬁcance in the PD and control subgroups when analyzed
independently; however, there were no interactions between MAPT
haplotype and PD, suggesting that this effect was consistent
regardless of disease status. These differences occurred in the
absence of differences in global cognitive function between genetic
groups as measured using the ACE-R. Our ﬁnding of an association
between MAPT haplotypes and speciﬁc memory deﬁcits is in
agreement with the results of a cohort study of 212 patients with PD
and mean disease duration of over 6 years, in which H1homozygosity was consistently associated with selective impair-
ments on the memory subscale of the Mattis Dementia Rating Scale
(Morley et al., 2012). The direction of effects also links in with our
previous observation of poorer cognitive outcome in H1 homo-
zygotes with PD (Evans et al., 2011; Goris et al., 2007) and the
well-established associations between H1 haplotype and risk for
neurodegenerative diseases characterized by dementia, including
progressive supranuclear palsy and corticobasal degeneration
(Caffrey and Wade-Martins, 2007). Despite a lack of association be-
tween MAPT haplotype and the risk of developing AD, H1 homozy-
gosity has been linked to an accelerated rate of conversion frommild
cognitive impairment to AD dementia (Samaranch et al., 2010).
Although it therefore appears that haplotypic variation in MAPT has
wide-reaching associations with cognitive function, its relationship
with cognitive progression in healthy aging is relatively unknown.
Our primary fMRI analysis revealed that activity in the medial
temporal lobes during encoding varied, depending onwhether or not
an item was subsequently remembered. The association between
increased medial temporal lobe activation during encoding and
success at recall is well described (Brewer et al., 1998; Ranganath and
D’Esposito, 2001), and the regions identiﬁed in our study are
consistent with those identiﬁed in a meta-analysis of fMRI studies
using similar subsequentmemory approaches: inferior frontal cortex,
bilateral fusiform cortex, bilateral hippocampal formation, bilateral
premotor cortex, and bilateral posterior parietal cortex (Kim, 2011).
Here, we show that this relationship between activation during
encoding and subsequent ability to recognize pictures varies as a
function of MAPT haplotype, irrespective of whether or not partic-
ipants had PD. More speciﬁcally, H1 homozygotes exhibited less
recruitment of the medial temporal lobe than H2 carriers during
encoding that was followed by successful recognition. On this basis,
we propose that there is an uncoupling of the normal relationship
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mance in this genetic group.
To explore this further, our second contrast looked at activation
during the overall engagement in the task, that is, encoding of im-
ages irrespective of whether theywere later recognized, in linewith
previous studies (Bookheimer et al., 2000). Here, we found that the
differences associated with MAPT haplotype were not uniform
across PD patients and control subjects. It was apparent that in the
PD group, but not in the control subjects, H1 homozygotes had
signiﬁcantly lessmedial temporal lobe activation thanH2 carriers. In
studies of AD, hypoactivation and hyperactivation of the medial
temporal lobehas been reportedduringmemory tasks in individuals
who are at risk of developing dementia. It has generally been sug-
gested that increased hippocampal activation is a compensatory
response that allows for the maintenance of relatively normal
memory function in the face of developing pathologic change (Bondi
et al., 2005; Bookheimer et al., 2000) and by inference, reduced
activation may reﬂect superior neuronal efﬁciency. However, in
situations such as that reported here, where the hypoactivation is
coupled with impaired memory performance, an alternative inter-
pretation is that the reduced medial temporal lobe activation may
relate to the detrimental effects of neurodegenerative change on
brain function (Machulda et al., 2003; Sperling et al., 2003).
We therefore postulate that the additional differences associated
withMAPT haplotype in our PD group could reﬂect the inﬂuence of
this genetic variant on a pathologic process leading to dementia.
Medial temporal lobe abnormalities have been described in PD
(Weintraub et al., 2012), and it is possible thatMAPThaplotype alters
the accumulation of pathology in these regions. Of particular rele-
vance, therefore, was the signiﬁcant negative correlation between
age and task-related activation that we observed exclusively among
the H1 homozygotes with PD. These age-dependent effects in H1
homozygotes coincide with our previous clinical ﬁndings of an
interaction between age andMAPThaplotype on cognitive decline in
PD, in which cognitive decline was age dependent in H1 homozy-
gotes but more static in H2 carriers (Goris et al., 2007).
Our ﬁnding of impaired behavioral performance in PD patients
relative to control subjects is consistent with previous reports of
memory deﬁcits in PD, even in patients without dementia (Aarsland
et al., 2010; Yarnall et al., 2014). Interestingly, however, despite these
differences in behavioral performance, we found no main differ-
ences associated with PD on activation in the temporal lobes during
successful encoding. One possibility is that the differences in
behavioral performance between PD patients and control subjects
could be explained by a mechanism that is distinct from memory
encoding per se. Of note, our behavioral outcomes and the desig-
nation of events during fMRI as being “remembered” or “non-
remembered” were based on a post-scan assessment. It is possible
that other factors contributed to performance in this assessment,
and these may not have manifested as differences in activation
which was recorded during picture presentation in the scanner. It
has, for example, beenproposed that some of thememory deﬁcits in
PD may be secondary to executive dysfunction, attentional impair-
ments, and disordered internally cued search strategies related to
frontostriatal dopamine disturbances. This has been supported by
the observation that, in contrast to AD, impaired recall in PD may
improvewith cueing, suggesting thatmemory impairment relates to
difﬁculties in the retrieval rather than the storage of information
(Helkala et al., 1988; Pillon et al., 1993).
In response to the question of whether structural differences are
contributing to the activation differences reported, we performed a
voxel-based morphometry to compare gray matter volumes be-
tween groups in the regions in which activation differences were
found (see Supplementary Material for details). There were differ-
ences associated with MAPT haplotype in the right hippocampus,and a trend in left hippocampus, but not the other regions analyzed.
However, whereas H1 haplotype was associated with reduced
activation, it was associated with increased gray matter volume,
suggesting that the activation differences we observed with fMRI
are not because of partial volume reductions in H1 haplotype car-
riers (i.e., hippocampal dysfunction but not simply hippocampal
atrophy). The mechanism of the relationship seen between MAPT
haplotype and brain function in this study remains to be deter-
mined. At a cellular level, there is accumulating evidence thatMAPT
haplotype inﬂuences tau transcription, with several studies
reporting that H1 haplotype is associatedwith increased expression
of total tau or of 4-repeat tau compared with the H2 haplotype
(Kwok et al., 2004; Myers et al., 2007; Rademakers et al., 2005;
Williams-Gray et al., 2009). The relative transcription of tau iso-
formswith 3 or 4microtubule-binding domains (3- or 4-repeat tau)
has been shown to be altered in PD (Tobin et al., 2008), and our own
study demonstrated that the H1 haplotype was associated with a
20% increase in 4-repeat tau transcription in PD brains (Williams-
Gray et al., 2009). Postmortem studies have supported the
concept that MAPT H1 haplotype drives Lewy body pathology
without any signiﬁcant contribution to Alzheimer’s type changes. In
one study of 22 cases of dementia with Lewy bodies, total Lewy
body counts and alpha-synuclein deposits were signiﬁcantly higher
among the H1 homozygotes than in the H2 carriers (Colom-Cadena
et al., 2013). A postmortem series of 762 cases of AD, Lewy body
diseases and vascular pathology linked H1 haplotype to reduced
Alzheimer’s type pathology and increased Lewy body counts
(Wider et al., 2012), and it is conceivable that the effect of H1 on
Lewy body accumulation may underlie the observation of acceler-
ated cognitive decline in clinically deﬁned AD cases inwhommixed
pathology is often seen (Samaranch et al., 2010).
However, given our observation that MAPT haplotypes are also
associatedwith differences in brain function in control subjects, it is
possible that these genetic variants exert effects on brain function
in aging more generally. These effects may either be related to
emergent pathologydfor example, the aforementioned accumula-
tion of Lewy bodiesdor could reﬂect a developmental inﬂuence,
comparable with recent suggestions of the pleiotrophic effects of
APOE polymorphisms in which the relative beneﬁcial and detri-
mental effects of a genetic variant vary over an individual’s lifetime
(Dean et al., 2014). Further behavioral and postmortem studies in
healthy control subjects and in different disease groups, at different
ages, are needed to clarify whether these effects occur earlier in
development or present only during aging.
Several limitations of this study should be considered. We
looked at 2 genetic groups to speciﬁcally follow up previous studies
which have reported differential effects in H1 homozygotes
compared with H2 carriers (Goris et al., 2007; Williams-Gray et al.,
2013); however, H2 homozygosity may be associated with a
different pattern of effects which could be further explored. The
patients were tested on L-dopa medication, however, critically,
doses were matched between the genetic subgroups and included
as covariates in the analysis, and should therefore not have
impacted on our primary aim which was to evaluate the effects of
MAPT haplotypes. Because of our a priori hypothesis, our analyses
were primarily focused on the effects of MAPT haplotypes on
temporal lobe regions. However, although there is evidence that PD
dementia is linked to posterior cortical dysfunction, there are likely
to be contributions from dysfunction across distributed brain re-
gions which warrant future study.
In conclusion, these ﬁndings endorse the fact that common hap-
lotypic variation inMAPT has important and clinically relevant asso-
ciations with cognitive function in PD and also implicate this genetic
variant in the function of the normal aging brain. We anticipate that
these ﬁndings will have implications for our understanding of
S.E. Winder-Rhodes et al. / Neurobiology of Aging xxx (2015) 1e10 9cognitive dysfunction in PD and also more broadly, with potential
applications in risk stratiﬁcation, prognostication, and the develop-
ment of appropriately targeted-treatment strategies.
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